Skip to main content

Macrogen to Use Genalice Data Processing for NGS Services

NEW YORK (GenomeWeb) – Dutch bioinformatics firm Genalice today said that Macrogen will use the firm's Genalice MAP for data processing as part of its next-generation sequencing analysis and services.

Genalice said that its MAP solution can process genomics data up to 100 times faster than conventional tools, while "radically" reducing storage requirements.

Seoul, South Korea-based Macrogen offers clinical sequencing services out of its CLIA-certified lab. The firm is planning to launch a healthcare information and content business using data from the Asian Genome Project and other genome networks, the firms said in a statement.

"A high-quality and fast pipeline for data processing and analysis is critical for providing better services for our customers as the genomics data production is soaring," Macrogen CEO Hyonyong Chong said. "With Genalice MAP, we can run our [Illumina] HiSeq X Ten systems to full capacity without having to build a large IT infrastructure and immediately share the results with our customers using a secure network connection instead of hard drives."

Terms of the alliance were not disclosed.

The deal follows Genalice's recent announcement of a partnership with Knome to jointly offer their products to customers as a turnkey solution for analyzing and interpreting next-generation sequencing data.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.